CN102196815A - 使用辐射和免疫细胞因子的癌症治疗 - Google Patents

使用辐射和免疫细胞因子的癌症治疗 Download PDF

Info

Publication number
CN102196815A
CN102196815A CN2009801417993A CN200980141799A CN102196815A CN 102196815 A CN102196815 A CN 102196815A CN 2009801417993 A CN2009801417993 A CN 2009801417993A CN 200980141799 A CN200980141799 A CN 200980141799A CN 102196815 A CN102196815 A CN 102196815A
Authority
CN
China
Prior art keywords
immunocytokine
tumor
days
radiation
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801417993A
Other languages
English (en)
Chinese (zh)
Inventor
T·威克姆
U·格纳德-福格特
S·G·克林兹
S·A·霍尔登
K·J·卡伦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CN102196815A publication Critical patent/CN102196815A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2009801417993A 2008-10-21 2009-10-21 使用辐射和免疫细胞因子的癌症治疗 Pending CN102196815A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10714608P 2008-10-21 2008-10-21
US61/107,146 2008-10-21
PCT/EP2009/007533 WO2010046097A1 (en) 2008-10-21 2009-10-21 Cancer treatments with radiation and immunocytokines

Publications (1)

Publication Number Publication Date
CN102196815A true CN102196815A (zh) 2011-09-21

Family

ID=41510762

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801417993A Pending CN102196815A (zh) 2008-10-21 2009-10-21 使用辐射和免疫细胞因子的癌症治疗

Country Status (12)

Country Link
US (1) US20100330029A1 (enExample)
EP (1) EP2337579A1 (enExample)
JP (1) JP2012506394A (enExample)
KR (1) KR20110086101A (enExample)
CN (1) CN102196815A (enExample)
AU (1) AU2009306711A1 (enExample)
BR (1) BRPI0919857A2 (enExample)
CA (1) CA2741130A1 (enExample)
EA (1) EA201100626A1 (enExample)
MX (1) MX2011004193A (enExample)
WO (1) WO2010046097A1 (enExample)
ZA (1) ZA201103726B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105992590A (zh) * 2014-02-19 2016-10-05 默克专利股份公司 靶定癌症的il-12免疫疗法
CN112768029A (zh) * 2020-12-27 2021-05-07 上海市东方医院（同济大学附属东方医院） 一种基于单细胞测序的组合用药推荐设备、方法及介质

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7165717B2 (ja) 2017-03-15 2022-11-04 パンディオン・オペレーションズ・インコーポレイテッド 標的免疫寛容
US9861833B1 (en) * 2017-03-30 2018-01-09 Norman H. Anderson Methods of treating melanoma
MX2019013517A (es) 2017-05-24 2020-08-17 Pandion Operations Inc Inmunotolerancia dirigida.
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
EP3972992A4 (en) 2019-05-20 2023-07-19 Pandion Operations, Inc. MADCAM TARGETED IMMUNOTLERANCE
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7186804B2 (en) * 2001-12-04 2007-03-06 Emd Lexigen Research Center Corp. IL-2 fusion proteins with modulated selectivity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2457701A (en) * 1999-12-28 2001-07-09 Brown University Research Foundation Methods and products for tumor immunotherapy using cytokines
ATE368475T1 (de) * 2000-06-29 2007-08-15 Emd Lexigen Res Ct Corp Steigerung von durch antikörper-zytokin- fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme
RU2007130552A (ru) * 2005-01-10 2009-02-20 Рисерч Дивелопмент Фаундейшн (US) Рекомбинантные молекулы направленного действия для лечения рака
PT1966238E (pt) * 2005-12-30 2012-07-31 Merck Patent Gmbh Uso de hsp70 como um regulador de atividade enzimática

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7186804B2 (en) * 2001-12-04 2007-03-06 Emd Lexigen Research Center Corp. IL-2 fusion proteins with modulated selectivity

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BEVERLY A.T. ET AL.: "IN VIVO studies with interleukin-12 alone and in combination with monocyte colony-stimulating factor and/or fractionated radiation treatment.", 《INT.J.CANCER》 *
刘世喜 等: "细胞因子基因联合放射治疗小鼠头颈部鳞状细胞癌的实验研究", 《中华耳鼻咽喉科杂志》 *
姬舒荣: "IL-12抗肿瘤免疫治疗及其基因治疗的研究进展", 《国外医学（免疫学分册）》 *
孙蒙: "应用IL- 12 进行肿瘤免疫治疗的新进展", 《国外医学（免疫学分册）》 *
魏道严 等: "病毒载体介导mIL-12基因治疗联合放射治疗小鼠肝癌的研究", 《中华放射医学与防护杂志》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105992590A (zh) * 2014-02-19 2016-10-05 默克专利股份公司 靶定癌症的il-12免疫疗法
CN105992590B (zh) * 2014-02-19 2019-12-31 默克专利股份公司 靶定癌症的il-12免疫疗法
CN112768029A (zh) * 2020-12-27 2021-05-07 上海市东方医院（同济大学附属东方医院） 一种基于单细胞测序的组合用药推荐设备、方法及介质
CN112768029B (zh) * 2020-12-27 2023-10-13 上海市东方医院（同济大学附属东方医院） 一种基于单细胞测序的组合用药推荐设备、方法及介质

Also Published As

Publication number Publication date
EA201100626A1 (ru) 2011-12-30
BRPI0919857A2 (pt) 2015-12-15
AU2009306711A1 (en) 2010-04-29
WO2010046097A1 (en) 2010-04-29
ZA201103726B (en) 2012-01-25
JP2012506394A (ja) 2012-03-15
KR20110086101A (ko) 2011-07-27
MX2011004193A (es) 2011-05-24
US20100330029A1 (en) 2010-12-30
CA2741130A1 (en) 2010-04-29
EP2337579A1 (en) 2011-06-29

Similar Documents

Publication Publication Date Title
CN102196815A (zh) 使用辐射和免疫细胞因子的癌症治疗
JP6240600B2 (ja) ヒト化免疫モノクローナル抗体の変異体
ES2943640T3 (es) Combinación de anticuerpos anti-PD-1 y radiación para tratar el cáncer
TWI751101B (zh) 對抗pd-1及pd-l1之拮抗劑與輻射療法組合之治療方法
EP1294401B1 (en) Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
Hovhannisyan et al. CAR T cell-based immunotherapy and radiation therapy: potential, promises and risks
CN109641963A (zh) 癌症的联合治疗
US20250235546A1 (en) Treatment of cancer using a combination of immunomodulation and check point inhibitors
EP3846855B1 (en) Cd47 blockade with parp inhibition for disease treatment
WO2022182483A1 (en) Methods for local and systemic treatment of cancers, tumors and tumor cells
JP2018516950A (ja) がん治療のための集中インターフェロン免疫療法
Sharon et al. Immunotherapy in head and neck squamous cell carcinoma: a narrative review
Castel et al. Treatment of high-risk neuroblastoma with anti-GD2 antibodies
CN110115767A (zh) 免疫调节剂联合检查点抑制剂治疗癌症的方法
ES3021110T3 (en) Immunomodulatory cytokines in combination with radiation treatment for unresectable pancreatic cancer
TWI865785B (zh) 包含含有il-2蛋白與cd80蛋白之融合蛋白的用於增強放射線治療的藥學組成物
US20230255978A1 (en) Methods for treating glioblastoma
EP4590325A1 (en) Il-21 fusion proteins useful as enhancers of anti-cancer immunotherapies
HK40088121A (zh) 用於治疗胶质母细胞瘤的方法
van Moorselaar Immunotherapy of renal cell carcinoma: clinical and experimental developments
HK1237670A1 (en) Methods of cancer treatment with antagonists against pd-1 and pd-l1 in combination with radiation therapy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20110921